

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Lollar
 Appl. No.: 10/813,507
 Filed: 3/30/04
 Confirmation No.: 5299
 Art Unit: 1645
 Examiner: To Be Assigned
 NUCLEIC ACID AND AMINO ACID SEQUENCES ENCODING HIGH-
 LEVEL EXPRESSOR FACTOR VIII POLYPEPTIDES AND METHODS OF
 USE

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
 CITATION UNDER 37 C.F.R. § 1.97**

Sir:

Attached is a list of documents on form PTO-1449. In accordance with the Office waiver published July 11, 2003, copies of the cited U.S. patents and patent application publications are not enclosed. Applicant does enclose copies of any cited foreign patent documents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

Respectfully submitted,

Kelly J. Williamson

Kelly J. Williamson
 Patent Agent
 Registration No. 47,179

CUSTOMER NO. 00826
ALSTON & BIRD LLP
 Bank of America Plaza
 101 South Tryon Street, Suite 4000
 Charlotte, NC 28280-4000
 Tel Raleigh Office (919) 862-2200
 Fax Raleigh Office (919) 862-2260

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on *July 20, 2004*

Pamela Lockley
 Pamela Lockley

Substitute for form 1449/PTO
(Revised 04/2003)

JUL 22 2004

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2 Attorney Docket Number 007157/279516

Complete if Known

Application Number	10/813,507
Filing Date	3/30/04
First Named Inventor	Lollar
Group Art Unit	1645
Examiner Name	To be Assigned

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
	1	US-5,364,771	11-15-1994	Lollar <i>et al.</i>	Whole Document
	2	US-5,583,209	12-10-1996	Lollar <i>et al.</i>	Whole Document
	3	US-5,663,060	09-02-1997	Lollar <i>et al</i>	Whole Document
	4	US-5,744,446	04-28-1998	Lollar <i>et al</i>	Whole Document
	5	US-5,859,204	01-12-1999	Lollar	Whole Document
	6	US-5,888,974	03-30-974	Lollar <i>et al</i>	Whole Document
	7	US-6,180,371	01-30-2001	Lollar	Whole Document
	8	US-6,376,463	04-23-2002	Lollar	Whole Document
	9	US-6,458,563	10-1-2002	Lollar	Whole Document


FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
-------------------	----------	--	--------------------------------	---	---	--

OTHER DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
.	10	BARROW, R.T., <i>et al.</i> , "Antigenicity of Putative Phospholipid Membrane-Binding Residues in Factor VIII," <i>Blood</i> , 2001, pp. 169-174, Vol. 97 No. 1.	
	11	BARROW, R.T., <i>et al.</i> , "Reduction of the Antigenicity of Factor VIII Toward Complex Inhibitory Antibody Plasmas Using Multiply-Substituted Hybrid Human/Porcine Factor VIII Molecules," <i>Blood</i> , 2000, pp. 564-568, Vol. 95, No. 2.	
	12	BOWIE, E.J., and C.A. Owen, "The Clinical and Laboratory Diagnosis of Hemorrhagic Disorders," <i>Grune & Stratton, Inc.</i> , Orlando, 1984, pp. 43-72.	
	13	CHANG, J., <i>et al.</i> , "Changing Residue 338 in Human Factor IX from Arginine to Alanine Causes an Increase in Catalytic Activity," <i>The Journal of Biological Chemistry</i> , 1998, pp. 12089-12094, Vol. 273, No. 20, The American Society for Biochemistry and Molecular Biology, Inc., USA.	
Examiner Signature		Date Considered	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449/PTO
(Revised 04/2003)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

				Complete if Known	
				Application Number	10/813,507
				Filing Date	3/30/04
				First Named Inventor	Lollar
				Group Art Unit	1645
				Examiner Name	To be Assigned
Sheet	1	of	2	Attorney Docket Number	007157/279516
	14	DOERING, C.B., <i>et al.</i> , "High Level Expression of Recombinant Porcine Coagulation Factor VIII," <i>The Journal of Biological Chemistry</i> , 2002, pp. 38345-38349, Vol. 277, No. 41, The American Society for Biochemistry and Molecular Biology, Inc., USA.			
	15	FUNK, W.D., <i>et al.</i> , "Expression of the Amino-Terminal Half-Molecule of Human Serum Transferrin in Cultured Cells and Characterization of Recombinant Protein," <i>Biochemistry</i> , 1990, pp. 1654-1660, Vol. 29, No. 6.			
	16	HEALEY, J.F., <i>et al.</i> , "Residues Glu2181-Val2243 Contain a Major Determinant of the Inhibitory Epitope in the C2 Domain of Human Factor VIII," <i>Blood</i> , 1998, pp. 3701-3709, Vol. 92, No. 10.			
	17	HEALEY, J.F., <i>et al.</i> , "Residues 484-508 Contain a Major Determinant of the Inhibitory Epitope in the A2 Domain of Human Factor VIII," <i>The Journal of Biological Chemistry</i> , 1995, pp. 14505-14509, Vol. 270, No. 24.			
	18	KAUFMAN, R.J., <i>et al.</i> , "Biosynthesis, Assembly and Secretion of Coagulation Factor VIII," <i>Blood Coagulation and Fibrinolysis</i> , 1997, pp. S3-S14, Vol. 8 (Suppl 2), Rapid science Publishers.			
	19	LIND, P., <i>et al.</i> , "Novel Forms of B-Domain-Deleted Recombinant Factor VIII Molecules Construction and Biochemical Characterization," <i>Eur. J. Biochem.</i> , 1995, pp. 19-27, Vol. 232.			
	20	LOLLAR, P., "Mapping factor VIII Inhibitor Epitopes Using Hybrid Human/Porcine Factor VIII Molecules," <i>Haematologica</i> , 2000, pp. 26-30, Vol. 85 (Suppl. to n. 10).			
	21	LUBIN, I.M., <i>et al.</i> , "Elimination of a Major Inhibitor Epitope in Factor VIII," <i>The Journal of Biological Chemistry</i> , 1994, pp. 8639-8641, Vol. 269, No. 12, The American Society for Biochemistry and Molecular Biology, Inc., USA.			
	22	PRESCOTT, R., <i>et al.</i> , "The Inhibitor Antibody Response is More Complex in Hemophilia A Patients Than in Most Nonhemophiliacs with Factor VIII Autoantibodies," <i>Blood</i> , 1997, pp. 3663-3671, Vol. 89, No. 10.			
	23	VEHAR, G.A., <i>et al.</i> , "Structure of Human Factor VIII," <i>Nature</i> , 1984, pp. 337-342, Vol. 312.			
	24	ZHONG, D., <i>et al.</i> , "Some Human Inhibitor Antibodies Interfere with Factor VIII Binding to Factor IX," 1998, pp. 136-142, Vol. 92, No. 1.			
Examiner Signature				Date Considered	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.